Cipla gets CDSCO panel nod to study Rizatriptan Benzoate Orally Disintegrating Tablet - Video
|
Overview
Granting approval to conduct bioequivalence (BE) study of Rizatriptan Benzoate Orally Disintegrating Tablets 5mg, the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has recommended the drug major Cipla to reduce sampling time points and blood volume during the study.
This came in wake of proposal presented by the drug major Cipla to manufacture and market Rizatriptan Benzoate Orally Disintegrating Tablets 5mg along with bioequivalence (BE) study protocol.
For more details, check out the full story on the link below:
Cipla Secure CDSCO Panel Nod To Study Rizatriptan Benzoate Orally Disintegrating Tablet
Speakers
Rahul Verma joined Medical Dialogues in the year 2022 and is currently working as a Video editor & Medical correspondent. He has completed his graduation in Bachelors of Arts (BA) from IGNOU. He likes to keep himself and the world updated on the occurring in the medical field. He can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
